Emerging HIV-1 resistance to tipranavir and darunavir in patients with virological failure to first-generation protease inhibitors in Taiwan
Journal
International Journal of STD and AIDS
Journal Volume
22
Journal Issue
11
Pages
617-620
Date Issued
2011
Author(s)
Abstract
Ritonavir-boosted tipranavir (TPV/r) and darunavir (DRV/r) have been approved in patients with virological resistance to multiple protease inhibitors (PIs). Whether the HIV-1 from these patients with virological failure to first-generation PIs remains susceptible to TPV/r or DRV/r is questionable. The susceptibilities of HIV-1 isolates to second-generation PIs in patients who experienced virological failure in three time periods were analysed: 9-2006 to 4-2007 (period 1), 5-2007 to 12-2007 (period 2) and 1-2008 to 8-2008 (period 3). A total of 53 subjects were enrolled, and 51 subject isolates (96.2%) were resistant to ?1 PIs. The mutation scores for TPV and DRV, and the percentage of isolates with resistance to TPV or DRV, increased significantly from period 1 to period 3. Our data revealed a significant increase in the levels of genotypic resistance to TPV and DRV over the past two years in patients with virological failure to first-generation PIs.
SDGs
Other Subjects
darunavir; darunavir plus ritonavir; proteinase inhibitor; ritonavir plus tipranavir; tipranavir; adult; article; drug treatment failure; female; genotype; human; Human immunodeficiency virus 1; Human immunodeficiency virus 1 infection; major clinical study; male; nonhuman; priority journal; Taiwan; virus isolation; virus resistance; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Mutation, Missense; Pyridines; Pyrones; Sulfonamides; Taiwan; Treatment Failure
Type
journal article